journal article·2023-07-28

Effects of Phospholipid Structure on the Acoustic Cavitation of Functionalized Mesoporous Silica Nanoparticles: Implications for Image-Guided Drug Delivery

Talaial B. Alina, Hunter B. Kirkpatrick, Natalie M. Bower, Shane D. Curry, Taylor R. Ausec, Sven A. Saemundsson, Evan N. Mueller, C. Wyatt Shields, Jennifer N. Cha, Andrew P. Goodwin

ACS Applied Nano Materials· Volume 6· Issue 14
Publisher page

Abstract

This study investigates the acoustic response of phospholipid-coated, hydrophobically modified mesoporous silica nanoparticles (PL-HMSNs) for image-guided drug delivery. PL-HMSNs were first stabilized with a PEGylated lipid, DSPE-PEG2k-methoxy, and the effect of particle concentration on the high-intensity focused ultrasound-induced cavitation threshold was explored. We found that increasing the particle concentration from 0 to 200 μg/mL decreased the acoustic pressure threshold for cavitation from ∼14 to ∼11 MPa, depending on the formulation. Dipalmitoylphosphatidylcholine (DPPC)-, distearoylphosphatidylcholine (DSPC)-, 1,2-dioleoyl- sn -glycero-3-phosphocholine (DOPC)-, and 1,2-dibehenoyl- sn -glycero-3-phosphocholine (DBPC)-HMSNs gave similar cavitation thresholds. Dilauroylphosphatidylcholine (DLPC)-stabilized particles showed little to no cavitation, which was attributed to DLPC’s high critical micelle concentration. DOPC-HMSNs had a higher uptake into HTB-9 human urinary bladder cancer cells than DSPC HMSNs, which is consistent with liposome delivery reports using unsaturated lipids. Finally, the effect of mixed lipid tail lengths was investigated by combining fluid-forming DOPC with gel-forming lipids. Cavitation signal intensities for mixed lipid-stabilized HMSNswere significantly higher than those for pure lipids, which was ascribed to reduced line tension of mixed lipids. Our findings highlight that higher particle concentrations and longer lipid tail lengths can lower the cavitation threshold of PL-HMSNs, and combining saturated lipids with DOPC can amplify the cavitation response. These results provide insights for optimizing lipid-stabilized solid ultrasound contrast agents for drug delivery applications and show how common lipid formulations can be imparted with acoustic activity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lipid Membrane Structure and Behavior · Electrostatics and Colloid Interactions · Ultrasound and Cavitation Phenomena

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, Colorado 80303, United States

Funding

National Cancer Institute · Office of Postsecondary Education · Division of Chemical, Bioengineering, Environmental, and Transport Systems

References (77)

Show source-provided references
1. Tomás-Pejó E. · 2011 · 14910.1016/B978-0-12-385099-7.00007-3 ↗
2. 10.1016/j.pbiomolbio.2006.07.00510.1016/j.pbiomolbio.2006.07.005 ↗
3. 10.1146/annurev.fluid.40.111406.10211610.1146/annurev.fluid.40.111406.102116 ↗
4. 10.1016/0041-624X(84)90006-410.1016/0041-624X(84)90006-4 ↗
5. 10.1121/1.38125210.1121/1.381252 ↗
6. 10.1073/pnas.171332811410.1073/pnas.1713328114 ↗
7. 10.1121/1.294299210.1121/1.2942992 ↗
8. 10.1121/1.39634910.1121/1.396349 ↗
9. 10.1115/1.402608910.1115/1.4026089 ↗
10. Holt R. · 2005
11. 10.1016/j.ultsonch.2013.05.00810.1016/j.ultsonch.2013.05.008 ↗
12. 10.1016/s0301-5629(96)00089-010.1016/s0301-5629(96)00089-0 ↗
13. 10.2214/ajr.09.332110.2214/ajr.09.3321 ↗
14. 10.1517/17425247.1.1.3710.1517/17425247.1.1.37 ↗
15. 10.1016/j.ultrasmedbio.2008.01.01610.1016/j.ultrasmedbio.2008.01.016 ↗
16. 10.1056/NEJM19880218318070110.1056/NEJM198802183180701 ↗
17. 10.1016/j.fertnstert.2005.04.07210.1016/j.fertnstert.2005.04.072 ↗
18. 10.1016/j.urology.2003.09.02010.1016/j.urology.2003.09.020 ↗
19. 10.1021/acs.langmuir.9b0079510.1021/acs.langmuir.9b00795 ↗
20. 10.1121/1.191653610.1121/1.1916536 ↗
21. 10.1007/s00330010094010.1007/s003300100940 ↗
22. 10.1158/0008-5472.CAN-12-012810.1158/0008-5472.CAN-12-0128 ↗
23. 10.2147/IJN.S13452510.2147/IJN.S134525 ↗
24. 10.1016/j.ultrasmedbio.2010.03.00510.1016/j.ultrasmedbio.2010.03.005 ↗
25. 10.1143/JJAP.49.07HF1810.1143/JJAP.49.07HF18 ↗
26. 10.1002/adma.20130165510.1002/adma.201301655 ↗
27. 10.1021/nn506789y10.1021/nn506789y ↗
28. 10.1039/c6nr08177k10.1039/c6nr08177k ↗
29. 10.1002/smll.20150132210.1002/smll.201501322 ↗
30. 10.7863/jum.2013.32.3.47510.7863/jum.2013.32.3.475 ↗
31. 10.1021/acs.jpcc.5b0725810.1021/acs.jpcc.5b07258 ↗
32. 10.1021/acs.langmuir.6b0336410.1021/acs.langmuir.6b03364 ↗
33. 10.1021/ja983582h10.1021/ja983582h ↗
34. 10.1021/ja00074a00410.1021/ja00074a004 ↗
35. 10.1002/adhm.20160003010.1002/adhm.201600030 ↗
36. 10.1109/TUFFC.2007.28010.1109/TUFFC.2007.280 ↗
37. 10.1093/jnci/djm04310.1093/jnci/djm043 ↗
38. 10.1016/S0378-5173(02)00129-110.1016/S0378-5173(02)00129-1 ↗
39. 10.1021/acs.biomac.2c0133810.1021/acs.biomac.2c01338 ↗
40. 10.1021/acs.langmuir.0c0026210.1021/acs.langmuir.0c00262 ↗
41. 10.1021/acs.langmuir.1c0027010.1021/acs.langmuir.1c00270 ↗
42. 10.1039/D1TB02823E10.1039/D1TB02823E ↗
43. 10.1016/j.plipres.2013.08.00510.1016/j.plipres.2013.08.005 ↗
44. 10.1038/s41598-020-58895-710.1038/s41598-020-58895-7 ↗
45. 10.1016/j.jconrel.2019.06.02510.1016/j.jconrel.2019.06.025 ↗
46. 10.1016/j.ultsonch.2006.09.01610.1016/j.ultsonch.2006.09.016 ↗
47. 10.1002/adhm.20170051410.1002/adhm.201700514 ↗
48. 10.3390/pharmaceutics1211106510.3390/pharmaceutics12111065 ↗
49. 10.1021/acsami.8b1536810.1021/acsami.8b15368 ↗
50. 10.1021/acs.chemmater.6b0263410.1021/acs.chemmater.6b02634 ↗
51. 10.7150/thno.1752210.7150/thno.17522 ↗
52. 10.1039/C6RA20328K10.1039/C6RA20328K ↗
53. 10.1002/adhm.20150031510.1002/adhm.201500315 ↗
54. 10.1016/j.cis.2022.10262010.1016/j.cis.2022.102620 ↗
55. 10.1016/j.cocis.2014.04.00810.1016/j.cocis.2014.04.008 ↗
56. 10.1016/j.canlet.2017.09.03710.1016/j.canlet.2017.09.037 ↗
57. 10.1016/S0006-3495(00)76295-310.1016/S0006-3495(00)76295-3 ↗
58. 10.1021/acsami.8b2265910.1021/acsami.8b22659 ↗
59. 10.1016/j.expthermflusci.2016.07.00910.1016/j.expthermflusci.2016.07.009 ↗
60. 10.1016/j.powtec.2019.11.06910.1016/j.powtec.2019.11.069 ↗
61. 10.1121/1.41630410.1121/1.416304 ↗
62. 10.1016/0301-5629(96)00104-410.1016/0301-5629(96)00104-4 ↗
63. 10.1121/1.39909110.1121/1.399091 ↗
64. 10.1021/bi00190a02210.1021/bi00190a022 ↗
65. 10.1021/la020476r10.1021/la020476r ↗
66. 10.1016/j.bbamem.2011.07.02210.1016/j.bbamem.2011.07.022 ↗
67. 10.1016/j.jddst.2020.10161610.1016/j.jddst.2020.101616 ↗
68. 10.1039/D2TB02197H10.1039/D2TB02197H ↗
69. 10.1002/jps.1000610.1002/jps.10006 ↗
70. 10.1080/23723556.2021.197427810.1080/23723556.2021.1974278 ↗
71. 10.1084/jem.2020160610.1084/jem.20201606 ↗
72. 10.1103/PhysRevE.53.267010.1103/PhysRevE.53.2670 ↗
73. 10.1103/PhysRevE.74.02191610.1103/PhysRevE.74.021916 ↗
74. 10.1021/la304768f10.1021/la304768f ↗
75. 10.1021/acs.jctc.8b0049610.1021/acs.jctc.8b00496 ↗
76. 10.1016/j.bbamem.2007.07.00810.1016/j.bbamem.2007.07.008 ↗
77. 10.1103/PhysRevLett.89.26810110.1103/PhysRevLett.89.268101 ↗